{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:25:22Z","timestamp":1793129122253,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01150-9","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:36:40Z","timestamp":1777477000000},"page":"421-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG)."],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-7830","authenticated-orcid":false,"given":"Anuj","family":"Maheshwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-8507","authenticated-orcid":false,"given":"Boon Wee","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsingh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichard","family":"Sukonthasarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadima","family":"Shegem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwajit","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf P.","family":"Valappil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-8949","authenticated-orcid":false,"given":"Antonia Anna","family":"Lukito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumerah","family":"Jabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla O.","family":"Al Hamaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Fawwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jam Chin","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-1051","authenticated-orcid":false,"given":"Deborah Ignacia D.","family":"Ona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eid","family":"Elsayed A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-1441","authenticated-orcid":false,"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohana Abdul","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesbah Sayed Kamel","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhashree","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2992-0735","authenticated-orcid":false,"given":"Raghunath","family":"Dantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"1150_CR1","volume":"16","author":"M Sharma","year":"2024","unstructured":"Sharma M, Gaidhane A, Choudhari SG. A comprehensive review on trends and patterns of non-communicable disease risk factors in India. Cureus. 2024;16:e57027.","journal-title":"Cureus"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.4103\/jfmpc.jfmpc_693_23","volume":"13","author":"S Sahu","year":"2024","unstructured":"Sahu S, Kumar S, Nagtode NR, Sahu M. \u201cThe burden of lifestyle diseases and their impact on health service in India\u201d\u2014A narrative review. J Family Med Prim Care. 2024;13:1612\u20139.","journal-title":"J Family Med Prim Care"},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1097\/JS9.0000000000002260","volume":"111","author":"J Li","year":"2025","unstructured":"Li J, Pandian V, Davidson PM, Song Y, Chen N, Fong DYT. Burden and attributable risk factors of non-communicable diseases and subtypes in 204 countries and territories, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Int J Surg. 2025;111:2385.","journal-title":"Int J Surg"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41371-023-00879-x","volume":"38","author":"A Talukder","year":"2024","unstructured":"Talukder A, Sara SS, Khan ZI, Yadav UN, Mistry SK, Biswas T, et al. Prevalence and determinants of hypertension in South-Asian Urban Communities: findings from Demographic and Health Surveys (DHS) data of South Asian countries. J Hum Hypertens. 2024;38:257\u201366.","journal-title":"J Hum Hypertens"},{"key":"1150_CR5","doi-asserted-by":"crossref","unstructured":"Shariff RER, Jiang H, Yap J, Tan SY, Cuenza L, Dwiputra B, et al. Overview of the Burden and Challenges of Hypertension in Asia-Pacific. 2024 Sep 6 [cited 2025 Jul 23]; Available from: https:\/\/www.japscjournal.com\/articles\/overview-burden-and-challenges-hypertension-asia-pacific?language_content_entity=en","DOI":"10.15420\/japsc.2024.35"},{"key":"1150_CR6","unstructured":"IDF Diabetes Atlas, 11th Edition [Internet]. International Diabetes Federation; 2025 [cited 2025 May 19]. Available from: https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/"},{"key":"1150_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11122-y","volume":"21","author":"Z Wang","year":"2021","unstructured":"Wang Z, Yang T, Fu H. Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: a cross-sectional study. BMC Public Health. 2021;21:1224.","journal-title":"BMC Public Health"},{"key":"1150_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14936","volume":"27","author":"WJ Wong","year":"2025","unstructured":"Wong WJ, Nguyen TV, Ahmad F, Vu HTT, Koh AS, Tan KM, et al. Hypertension in adults with diabetes in southeast asia: a systematic review. J Clin Hypertens (Greenwich). 2025;27:e14936.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"e052393","DOI":"10.1136\/bmjopen-2021-052393","volume":"12","author":"OA Uthman","year":"2022","unstructured":"Uthman OA, Ayorinde A, Oyebode O, Sartori J, Gill P, Lilford RJ. Global prevalence and trends in hypertension and type 2 diabetes mellitus among slum residents: a systematic review and meta-analysis. BMJ Open. 2022;12:e052393.","journal-title":"BMJ Open"},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.59556\/japi.72.0620","volume":"72","author":"GS Wander","year":"2024","unstructured":"Wander GS, Panda JK, Pal J, Mathur G, Sahay R, Tiwaskar M, et al. Management of hypertension in patients with type 2 diabetes mellitus: Indian guideline 2024 by association of physicians of India and Indian college of physicians. J Assoc Physicians India. 2024;72:e1\u201325.","journal-title":"J Assoc Physicians India"},{"key":"1150_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s13410-022-01143-7","volume":"42","author":"V Kumar","year":"2022","unstructured":"Kumar V, Agarwal S, Saboo B, Makkar B. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus. Int J Diabetes Dev Ctries. 2022;42:576\u2013605.","journal-title":"Int J Diabetes Dev Ctries"},{"key":"1150_CR12","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","volume":"82","author":"DW Jones","year":"2025","unstructured":"Writing Committee Members*, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82:e212\u2013316.","journal-title":"Hypertension"},{"key":"1150_CR13","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"1150_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"key":"1150_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.61081\/htnj\/23v9i302","volume":"9","author":"R Gupta","year":"2023","unstructured":"Gupta R, Maheshwari A, Verma N, Narasingan S, Tripathi K. InSH consensus guideline for the management of hypertension, 2023. Hypertens J. 2023;9:57\u2013132.","journal-title":"Hypertens J"},{"key":"1150_CR16","first-page":"e46687","volume":"15","author":"S Davalagi","year":"2023","unstructured":"Davalagi S, Amuje R, H S. Cardiovascular risk assessment among people with type 2 diabetes mellitus in urban slums of central Karnataka, India. Cureus. 2023;15:e46687.","journal-title":"Cureus"},{"key":"1150_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/ijcm.ijcm_825_21","volume":"47","author":"R Kannan","year":"2022","unstructured":"Kannan R, Kiran PR, Gnanaselvam NA, Mathew KG, Johnson JC. \u201cHealthy Heart, Healthy You\u201d: Ten-Year Cardiovascular Disease (CVD) Risk among Adults in Anekal Taluk Hospital, Bangalore Urban District, Karnataka. Indian J Community Med. 2022;47:429\u201332.","journal-title":"Indian J Community Med"},{"key":"1150_CR18","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"key":"1150_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1407918","volume":"12","author":"A Mamgai","year":"2024","unstructured":"Mamgai A, Halder P, Behera A, Goel K, Pal S, Amudhamozhi KS, et al. Cardiovascular risk assessment using non-laboratory based WHO CVD risk prediction chart with respect to hypertension status among older Indian adults: insights from nationally representative survey. Front Public Health. 2024;12:1407918.","journal-title":"Front Public Health"},{"key":"1150_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/eurheartj\/ehae609","volume":"46","author":"SHJ Hageman","year":"2025","unstructured":"SCORE2 Asia-Pacific writing group, Hageman SHJ, Huang Z, Lee H, Kaptoge S, Dorresteijn JAN, et al. Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model. Eur Heart J. 2025;46:702\u201315.","journal-title":"Eur Heart J"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/CIRCRESAHA.121.318083","volume":"128","author":"RM Carey","year":"2021","unstructured":"Carey RM, Wright JT, Taler SJ, Whelton PK. Guideline-Driven Management of Hypertension. Circ Res. 2021;128:827\u201346.","journal-title":"Circ Res"},{"key":"1150_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.focha.2023.100406","volume":"3","author":"YP Timsina","year":"2023","unstructured":"Timsina YP, Pandey P, Mondal IH, Dar AH. Non-pharmacological management of hypertension: A systematic review. Food Chem Adv. 2023;3:100406.","journal-title":"Food Chem Adv"},{"key":"1150_CR23","doi-asserted-by":"publisher","DOI":"10.1029\/2024GH001014","volume":"8","author":"J Madrigano","year":"2024","unstructured":"Madrigano J, Yan D, Liu T, Bonilla E, Yulianti N, Mickley LJ, et al. Air Pollution and Blood Pressure: Evidence From Indonesia. Geohealth. 2024;8:e2024GH001014.","journal-title":"Geohealth"},{"key":"1150_CR24","volume":"20","author":"K Saleem","year":"2025","unstructured":"Saleem K, Iahtisham-Ul-Haq, Abdi G, Rabail R, Aadil RM. Dietary and lifestyle modifications for effective management of hypertension: A comprehensive review. J Agric Food Res. 2025;20:101750.","journal-title":"J Agric Food Res"},{"key":"1150_CR25","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/NHA-170036","volume":"4","author":"K Gabel","year":"2018","unstructured":"Gabel K, Hoddy KK, Haggerty N, Song J, Kroeger CM, Trepanowski JF, et al. Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study. Nutr Healthy Aging. 2018;4:345\u201353.","journal-title":"Nutr Healthy Aging"},{"key":"1150_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3945\/an.115.009753","volume":"7","author":"RN Ndanuko","year":"2016","unstructured":"Ndanuko RN, Tapsell LC, Charlton KE, Neale EP, Batterham MJ. Dietary patterns and blood pressure in adults: a systematic review and meta-analysis of randomized controlled Trials12. Adv Nutr. 2016;7:76\u201389.","journal-title":"Adv Nutr"},{"key":"1150_CR27","first-page":"1228","volume":"31","author":"J Xueyan","year":"2023","unstructured":"Xueyan J, Kunpeng S, Ning Z, Luyao LIU, Yifan Z, Yun C, et al. Effect of heart-healthy dietary patterns on blood pressure: a systematic review and meta-analysis. zhgxyzz. 2023;31:1228\u201337.","journal-title":"zhgxyzz"},{"key":"1150_CR28","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.3390\/nu15143261","volume":"15","author":"X Theodoridis","year":"2023","unstructured":"Theodoridis X, Chourdakis M, Chrysoula L, Chroni V, Tirodimos I, Dipla K, et al. Adherence to the DASH diet and risk of hypertension: a systematic review and meta-analysis. Nutrients. 2023;15:3261.","journal-title":"Nutrients"},{"key":"1150_CR29","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/advances\/nmaa041","volume":"11","author":"CD Filippou","year":"2020","unstructured":"Filippou CD, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimitriadis KS, Sotiropoulou LI, et al. Dietary Approaches to Stop Hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2020;11:1150\u201360.","journal-title":"Adv Nutr"},{"key":"1150_CR30","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117\u2013314.","journal-title":"Kidney Int"},{"key":"1150_CR31","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41440-025-02181-4","volume":"48","author":"E Mizuta","year":"2025","unstructured":"Mizuta E, Kitada K, Nagata S, Ogura S, Sakima A, Suzuki J, et al. Effect of population-based sodium reduction interventions on blood pressure: a systematic review and meta-analysis of randomized trials. Hypertens Res. 2025;48:1899\u2013910.","journal-title":"Hypertens Res"},{"key":"1150_CR32","doi-asserted-by":"publisher","first-page":"e032941","DOI":"10.1136\/bmjopen-2019-032941","volume":"10","author":"A Jin","year":"2020","unstructured":"Jin A, Xie W, Wu Y. Effect of salt reduction interventions in lowering blood pressure in Chinese populations: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2020;10:e032941.","journal-title":"BMJ Open"},{"key":"1150_CR33","doi-asserted-by":"publisher","first-page":"m315","DOI":"10.1136\/bmj.m315","volume":"368","author":"L Huang","year":"2020","unstructured":"Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell NRC, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020;368:m315.","journal-title":"BMJ"},{"key":"1150_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015719","volume":"9","author":"T Filippini","year":"2020","unstructured":"Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9:e015719.","journal-title":"J Am Heart Assoc"},{"key":"1150_CR35","doi-asserted-by":"publisher","first-page":"e0174967","DOI":"10.1371\/journal.pone.0174967","volume":"12","author":"J Poorolajal","year":"2017","unstructured":"Poorolajal J, Zeraati F, Soltanian AR, Sheikh V, Hooshmand E, Maleki A. Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials. PLoS ONE. 2017;12:e0174967.","journal-title":"PLoS ONE"},{"key":"1150_CR36","doi-asserted-by":"crossref","unstructured":"Gaya PV, Fonseca GWP, Tanji LT, Abe TO, Alves MJNN, de Lima Santos PCJ, et al. Smoking cessation decreases arterial blood pressure in hypertensive smokers: A subgroup analysis of the randomized controlled trial GENTSMOKING. Tob Induc Dis. 2024;22.","DOI":"10.18332\/tid\/186853"},{"key":"1150_CR37","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/HYPERTENSIONAHA.124.22703","volume":"81","author":"M Cecchini","year":"2024","unstructured":"Cecchini M, Filippini T, Whelton PK, Iamandii I, Di Federico S, Boriani G, et al. Alcohol intake and risk of hypertension: a systematic review and dose-response meta-analysis of nonexperimental cohort studies. Hypertension. 2024;81:1701\u201315.","journal-title":"Hypertension"},{"key":"1150_CR38","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","volume":"2","author":"M Roerecke","year":"2017","unstructured":"Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2:e108\u201320.","journal-title":"Lancet Public Health"},{"key":"1150_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00394-017-1591-z","volume":"58","author":"L D\u2019Elia","year":"2019","unstructured":"D\u2019Elia L, La Fata E, Galletti F, Scalfi L, Strazzullo P. Coffee consumption and risk of hypertension: a dose-response meta-analysis of prospective studies. Eur J Nutr. 2019;58:271\u201380.","journal-title":"Eur J Nutr"},{"key":"1150_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011318","volume":"8","author":"SA Shah","year":"2019","unstructured":"Shah SA, Szeto AH, Farewell R, Shek A, Fan D, Quach KN, et al. Impact of high volume energy drink consumption on electrocardiographic and blood pressure parameters: a randomized trial. J Am Heart Assoc. 2019;8:e011318.","journal-title":"J Am Heart Assoc"},{"key":"1150_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02511-9","volume":"18","author":"MA Farhangi","year":"2020","unstructured":"Farhangi MA, Nikniaz L, Khodarahmi M. Sugar-sweetened beverages increases the risk of hypertension among children and adolescence: a systematic review and dose-response meta-analysis. J Transl Med. 2020;18:344.","journal-title":"J Transl Med"},{"key":"1150_CR42","doi-asserted-by":"crossref","unstructured":"Li B, Yan N, Jiang H, Cui M, Wu M, Wang L, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages and fruit juices and risk of type 2 diabetes, hypertension, cardiovascular disease, and mortality: A meta-analysis. Front Nutr [Internet]. 2023 Mar 15 [cited 2025 May 26];10. Available from: https:\/\/www.frontiersin.org\/journals\/nutrition\/articles\/10.3389\/fnut.2023.1019534\/full","DOI":"10.3389\/fnut.2023.1019534"},{"key":"1150_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/jch.14661","volume":"25","author":"S Yang","year":"2023","unstructured":"Yang S, Zhou Z, Miao H, Zhang Y. Effect of weight loss on blood pressure changes in overweight patients: A systematic review and meta\u2010analysis. J Clin Hypertens (Greenwich). 2023;25:404\u201315.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1150_CR44","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1007\/s11606-021-06655-2","volume":"36","author":"Y Gepner","year":"2021","unstructured":"Gepner Y, Goldstein N, Shelef I, Schwarzfuchs D, Zelicha H, Meir AY, et al. Dissociation between long-term weight loss intervention and blood pressure: an 18-month randomized controlled trial. J Gen Intern Med. 2021;36:2300\u20136.","journal-title":"J Gen Intern Med"},{"key":"1150_CR45","first-page":"116","volume":"31","author":"FA J\u00fanior","year":"2020","unstructured":"J\u00fanior FA, Samuel GG, da Silva FF, Oliveira EC, Coelho DB, Becker LK, et al. The effects of aquatic and land exercise on resting blood pressure and post-exercise hypotension response in elderly hypertensives. Cardiovasc J Afr. 2020;31:116\u201322.","journal-title":"Cardiovasc J Afr"},{"key":"1150_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2786120","volume":"2020","author":"M Kazeminia","year":"2020","unstructured":"Kazeminia M, Daneshkhah A, Jalali R, Vaisi-Raygani A, Salari N, Mohammadi M. The effect of exercise on the older adult\u2019s blood pressure suffering hypertension: systematic review and meta-analysis on clinical trial studies. Int J Hypertens. 2020;2020:2786120.","journal-title":"Int J Hypertens"},{"key":"1150_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.116.08994","volume":"69","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang D, Liu Y, Sun X, Han C, Wang B, et al. Dose-response association between physical activity and incident hypertension: a systematic review and meta-analysis of cohort studies. Hypertension. 2017;69:813\u201320.","journal-title":"Hypertension"},{"key":"1150_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111657","volume":"158","author":"L Carpes","year":"2022","unstructured":"Carpes L, Costa R, Schaarschmidt B, Reichert T, Ferrari R. High-intensity interval training reduces blood pressure in older adults: a systematic review and meta-analysis. Exp Gerontol. 2022;158:111657.","journal-title":"Exp Gerontol"},{"key":"1150_CR49","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/08037051.2021.1940837","volume":"30","author":"GA Kelley","year":"2021","unstructured":"Kelley GA, Kelley KS, Stauffer BL. Isometric exercise and inter-individual response differences on resting systolic and diastolic blood pressure in adults: a meta-analysis of randomized controlled trials. Blood Press. 2021;30:310\u201321.","journal-title":"Blood Press"},{"key":"1150_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.893811","volume":"9","author":"G Saco-Ledo","year":"2022","unstructured":"Saco-Ledo G, Valenzuela PL, Ruilope LM, Lucia A. Physical exercise in resistant hypertension: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022;9:893811.","journal-title":"Front Cardiovasc Med"},{"key":"1150_CR51","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/sms.13949","volume":"31","author":"M Ramirez-Jimenez","year":"2021","unstructured":"Ramirez-Jimenez M, Morales-Palomo F, Moreno-Caba\u00f1as A, Alvarez-Jimenez L, Ortega JF, Mora-Rodriguez R. Effects of antihypertensive medication and high-intensity interval training in hypertensive metabolic syndrome individuals. Scand J Med Sci Sports. 2021;31:1411\u20139.","journal-title":"Scand J Med Sci Sports"},{"key":"1150_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2023.100882","volume":"15","author":"N Ahuja","year":"2024","unstructured":"Ahuja N, Bhardwaj P, Pathania M, Sethi D, Kumar A, Parchani A, et al. Yoga Nidra for hypertension: A systematic review and meta-analysis. J Ayurveda Integr Med. 2024;15:100882.","journal-title":"J Ayurveda Integr Med"},{"key":"1150_CR53","doi-asserted-by":"crossref","unstructured":"Nalbant G, Hassanein ZM, Lewis S, Chattopadhyay K Content, Structure, and Delivery Characteristics of Yoga Interventions for Managing Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Public Health [Internet]. 2022 Mar 28 [cited 2025 May 27];10. Available from: https:\/\/www.frontiersin.org\/journals\/public-health\/articles\/10.3389\/fpubh.2022.846231\/full","DOI":"10.3389\/fpubh.2022.846231"},{"key":"1150_CR54","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.mayocp.2018.09.023","volume":"94","author":"Y Wu","year":"2019","unstructured":"Wu Y, Johnson BT, Acabchuk RL, Chen S, Lewis HK, Livingston J, et al. Yoga as Antihypertensive Lifestyle Therapy: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2019;94:432\u201346.","journal-title":"Mayo Clin Proc"},{"key":"1150_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2024.103084","volume":"85","author":"IA Mir","year":"2024","unstructured":"Mir IA, John AT, Humayra S, Khan QI, Chong TF, Manan HA. Effect of mindfulness-based meditation on blood pressure among adults with elevated blood pressure and hypertension: A systematic review of randomized controlled trials. Complement Ther Med. 2024;85:103084.","journal-title":"Complement Ther Med"},{"key":"1150_CR56","unstructured":"Subburayan Y Education about Hypertension and Its Impact on Knowledge, Lifestyle Choices, and Blood Pressure Control in the UK: A Systematic Review. Journal of Community Medicine & Public Health [Internet]. 2023 Aug 4 [cited 2025 May 27]; Available from: https:\/\/www.gavinpublishers.com\/article\/view\/education-about-hypertension-and-its-impact-on-knowledge-lifestyle-choices-and-blood-pressure-control-in-the-uk-a-systematic-review"},{"key":"1150_CR57","first-page":"1959","volume":"31","author":"K Manzoor","year":"2024","unstructured":"Manzoor K, Kausar PDS, Ghani DM. Effectiveness of patient\u2019s education in self-management of blood pressure in hypertensive patients. J Popl Ther Clin Pharmacol. 2024;31:1959\u201368.","journal-title":"J Popl Ther Clin Pharmacol"},{"key":"1150_CR58","doi-asserted-by":"publisher","first-page":"e048079","DOI":"10.1136\/bmjopen-2020-048079","volume":"12","author":"M Cernota","year":"2022","unstructured":"Cernota M, Kroeber ES, Demeke T, Frese T, Getachew S, Kantelhardt EJ, et al. Non-pharmacological interventions to achieve blood pressure control in African patients: a systematic review. BMJ Open. 2022;12:e048079.","journal-title":"BMJ Open"},{"key":"1150_CR59","first-page":"764","volume":"36","author":"N Stogios","year":"2020","unstructured":"Stogios N, Kaur B, Huszti E, Vasanthan J, Nolan RP. Advancing digital health interventions as a clinically applied science for blood pressure reduction: a systematic review and meta-analysis. Can J Cardiol. 2020;36:764\u201374.","journal-title":"Can J Cardiol"},{"key":"1150_CR60","doi-asserted-by":"publisher","first-page":"e2356070","DOI":"10.1001\/jamanetworkopen.2023.56070","volume":"7","author":"ME Katz","year":"2024","unstructured":"Katz ME, Mszar R, Grimshaw AA, Gunderson CG, Onuma OK, Lu Y, et al. Digital health interventions for hypertension management in US populations experiencing health disparities: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:e2356070.","journal-title":"JAMA Netw Open"},{"key":"1150_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102432","volume":"69","author":"V Boima","year":"2024","unstructured":"Boima V, Doku A, Agyekum F, Tuglo LS, Agyemang C. Effectiveness of digital health interventions on blood pressure control, lifestyle behaviours and adherence to medication in patients with hypertension in low-income and middle-income countries: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2024;69:102432.","journal-title":"EClinicalMedicine"},{"key":"1150_CR62","first-page":"341","volume":"101","author":"DK Smith","year":"2020","unstructured":"Smith DK, Lennon RP, Carlsgaard PB. Managing hypertension using combination therapy. AFP. 2020;101:341\u20139.","journal-title":"AFP"},{"key":"1150_CR63","doi-asserted-by":"publisher","first-page":"212531","DOI":"10.7573\/dic.212531","volume":"7","author":"C Guerrero-Garc\u00eda","year":"2018","unstructured":"Guerrero-Garc\u00eda C, Rubio-Guerra AF. Combination therapy in the treatment of hypertension. Drugs Context. 2018;7:212531.","journal-title":"Drugs Context"},{"key":"1150_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-141","volume":"11","author":"LM Brewster","year":"2013","unstructured":"Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and \u03b2-adrenergic blockers? A systematic review. BMC Med. 2013;11:141.","journal-title":"BMC Med"},{"key":"1150_CR65","volume":"16","author":"Y Khan","year":"2024","unstructured":"Khan Y, Shanmugar SB, Ahmad UF, Mansoor A, Gbamgbola TA, Farooq W, et al. The implementation and outcomes of personalized antihypertensive therapy based on pharmacogenetic testing: a retrospective study examining blood pressure control and medication tolerability. Cureus. 2024;16:e74288.","journal-title":"Cureus"},{"key":"1150_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejim.2024.04.011","volume":"126","author":"A Coca","year":"2024","unstructured":"Coca A, Whelton S, Camafort M, L\u00f3pez-L\u00f3pez J, Yang E. Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit? Eur J Intern Med. 2024;126:16\u201325.","journal-title":"Eur J Intern Med"},{"key":"1150_CR67","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Rueter P, Atkins E, Webster R, Huffman M, de Silva A, et al. Efficacy and safety of low-dose triple and quadruple combination pills vs monotherapy, usual care, or placebo for the initial management of hypertension: a systematic review and meta-analysis. JAMA Cardiol. 2023;8:606\u201311.","journal-title":"JAMA Cardiol"},{"key":"1150_CR68","doi-asserted-by":"publisher","unstructured":"Elgendy MS, Taha HI, Amin AM, Khlidj Y, Ezz MR, Elgamasy MA, et al. The efficacy and safety of low-dose triple combination for hypertension treatment: a systematic review and meta-analysis of randomized controlled trials. Naunyn-Schmiedeberg\u2019s Arch Pharmacol [Internet]. 2025 Feb 6 [cited 2025 May 31]; Available from: https:\/\/doi.org\/10.1007\/s00210-025-03790-z","DOI":"10.1007\/s00210-025-03790-z"},{"key":"1150_CR69","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1097\/HJH.0000000000002096","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37:1768\u201374.","journal-title":"J Hypertens"},{"key":"1150_CR70","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/HJH.0000000000001608","volume":"36","author":"S Omboni","year":"2018","unstructured":"Omboni S, Kario K, Bakris G, Parati G. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018;36:720.","journal-title":"J Hypertens"},{"key":"1150_CR71","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320:566\u201379.","journal-title":"JAMA"},{"key":"1150_CR72","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/clc.24082","volume":"46","author":"M Xie","year":"2023","unstructured":"Xie M, Tang T, Liang H. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. Clin Cardiol. 2023;46:886\u201398.","journal-title":"Clin Cardiol"},{"key":"1150_CR73","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703\u201313.","journal-title":"BMJ"},{"key":"1150_CR74","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahl\u00f6f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755\u201362.","journal-title":"Lancet"},{"key":"1150_CR75","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829\u201340.","journal-title":"Lancet"},{"key":"1150_CR76","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61\u20138.","journal-title":"JAMA"},{"key":"1150_CR77","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"The ACCORD Study Group","year":"2010","unstructured":"The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1150_CR78","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2337\/dc17-1366","volume":"40","author":"LF Buckley","year":"2017","unstructured":"Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-Eligible participants of ACCORD-BP. Diabetes Care. 2017;40:1733\u20138.","journal-title":"Diabetes Care"},{"key":"1150_CR79","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385:1268\u201379.","journal-title":"N Engl J Med"},{"key":"1150_CR80","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404:245\u201355.","journal-title":"Lancet"},{"key":"1150_CR81","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025;392:1155\u201367.","journal-title":"N Engl J Med"},{"key":"1150_CR82","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/jebm.12655","volume":"17","author":"X Pan","year":"2024","unstructured":"Pan X, He H, Bao Y, Bi Y, Chen L, Chen X, et al. Chinese expert consensus on the management of hypertension in adults with type 2 diabetes. J Evid Based Med. 2024;17:851\u201364.","journal-title":"J Evid Based Med"},{"key":"1150_CR83","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/08037051.2022.2071674","volume":"31","author":"EH Groenland","year":"2022","unstructured":"Groenland EH, Bots ML, Visseren FLJ, McManus RJ, Spiering W. Number of measurement days needed for obtaining a reliable estimate of home blood pressure and hypertension status. Blood Press. 2022;31:100\u20138.","journal-title":"Blood Press"},{"key":"1150_CR84","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ihj.2023.12.009","volume":"76","author":"G Satheesh","year":"2024","unstructured":"Satheesh G, Dhurjati R, Balagopalan JP, Mohanan PP, Salam A. Comparison of Indian clinical practice guidelines for the management of hypertension with the World Health Organization, International Society of Hypertension, American, and European guidelines. Indian Heart J. 2024;76:6\u20139.","journal-title":"Indian Heart J"},{"key":"1150_CR85","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140.","journal-title":"Eur Heart J"},{"key":"1150_CR86","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40119-024-00381-6","volume":"13","author":"M Sobhy","year":"2024","unstructured":"Sobhy M, Eletriby A, Ragy H, Kandil H, Saleh MA, Farag N, et al. ACE Inhibitors and angiotensin receptor blockers for the primary and secondary prevention of cardiovascular outcomes: recommendations from the 2024 Egyptian cardiology expert consensus in collaboration with the CVREP foundation. Cardiol Ther. 2024;13:707\u201336.","journal-title":"Cardiol Ther"},{"key":"1150_CR87","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension. JACC. 2018;71:1474\u201382.","journal-title":"JACC"},{"key":"1150_CR88","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1471-2261-14-148","volume":"14","author":"G Hao","year":"2014","unstructured":"Hao G, Wang Z, Guo R, Chen Z, Wang X, Zhang L, et al. Effects of ACEI\/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord. 2014;14:148.","journal-title":"BMC Cardiovasc Disord"},{"key":"1150_CR89","volume":"16","author":"TS Peresuodei","year":"2024","unstructured":"Peresuodei TS, Gill A, Orji C, Reghefaoui M, Saavedra Palacios MS, Nath TS. A Comparative Study of the Safety and Efficacy Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Management of Hypertension: A Systematic Review. Cureus. 2024;16:e54311.","journal-title":"Cureus"},{"key":"1150_CR90","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1159\/000489913","volume":"43","author":"K Wang","year":"2018","unstructured":"Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of Angiotensin-Converting enzyme inhibitors and Angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43:768\u201379.","journal-title":"Kidney Blood Press Res"},{"key":"1150_CR91","doi-asserted-by":"publisher","first-page":"e0256","DOI":"10.1097\/MD.0000000000010256","volume":"97","author":"X Lv","year":"2018","unstructured":"Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis. Medicine. 2018;97:e0256.","journal-title":"Medicine"},{"key":"1150_CR92","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/ndt\/gfab048","volume":"37","author":"B Tian","year":"2022","unstructured":"Tian B, Deng Y, Cai Y, Han M, Xu G. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37:720\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1150_CR93","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41440-025-02146-7","volume":"48","author":"D Ichikawa","year":"2025","unstructured":"Ichikawa D, Kawarazaki W, Saka S, Kanaoka T, Ohnishi H, Arima H, et al. Efficacy of renin-angiotensin system inhibitors, calcium channel blockers, and diuretics in hypertensive patients with diabetes: subgroup analysis based on albuminuria in a systematic review and meta-analysis. Hypertens Res. 2025;48:1880\u201390.","journal-title":"Hypertens Res"},{"key":"1150_CR94","doi-asserted-by":"crossref","unstructured":"Chen S, Tian P, Estau D, Li Z. Effects of \u03b2-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Front Cell Dev Biol [Internet]. 2023. https:\/\/www.frontiersin.org\/journals\/cell-and-developmental-biology\/articles\/10.3389\/fcell.2023.1076107\/full Jan 27 [cited 2025 May 28];11. Available from:","DOI":"10.3389\/fcell.2023.1076107"},{"key":"1150_CR95","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.117.09259","volume":"70","author":"T Tsujimoto","year":"2017","unstructured":"Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on \u03b2-blockers. Hypertension. 2017;70:103\u201310.","journal-title":"Hypertension"},{"key":"1150_CR96","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"1150_CR97","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01564-3","volume":"18","author":"OJ Ziff","year":"2020","unstructured":"Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med. 2020;18:103.","journal-title":"BMC Med"},{"key":"1150_CR98","doi-asserted-by":"publisher","first-page":"113","DOI":"10.36011\/cpp.2023.5.e16","volume":"5","author":"EM Lee","year":"2023","unstructured":"Lee EM. Calcium channel blockers for hypertension: old, but still useful. CPP. 2023;5:113\u201325.","journal-title":"CPP"},{"key":"1150_CR99","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48:S207\u201338.","journal-title":"Diabetes Care"},{"key":"1150_CR100","first-page":"11273","volume":"10","author":"Y Xiao","year":"2017","unstructured":"Xiao Y, Hu G. The effects of azelnidipine and amlodipine in treatment of mild to moderate hypertension: A systematic review. Int J Clin Exp Med. 2017;10:11273\u201381.","journal-title":"Int J Clin Exp Med"},{"key":"1150_CR101","doi-asserted-by":"publisher","first-page":"e0125519","DOI":"10.1371\/journal.pone.0125519","volume":"10","author":"M Takihata","year":"2015","unstructured":"Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 diabetic patients with hypertension: the COAT randomized controlled trial. PLoS ONE. 2015;10:e0125519.","journal-title":"PLoS ONE"},{"key":"1150_CR102","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40200-024-01538-9","volume":"24","author":"J Tewari","year":"2025","unstructured":"Tewari J, Qidwai KA, Roy S, Rana A, Kumar S, Sonkar SK, et al. Azelnidipine and its role in decreasing urinary albumin creatinine ratio in people with type 2 diabetes and hypertension: a systematic review and meta-analysis. J Diabetes Metab Disord. 2025;24:7.","journal-title":"J Diabetes Metab Disord"},{"key":"1150_CR103","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13098-015-0073-9","volume":"7","author":"K Tawaramoto","year":"2015","unstructured":"Tawaramoto K, Kaneto H, Hashiramoto M, Kawasaki F, Tatsumi F, Shimoda M, et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr. 2015;7:80.","journal-title":"Diabetol Metab Syndr"},{"key":"1150_CR104","first-page":"e19822","volume":"13","author":"RN Chakraborty","year":"2021","unstructured":"Chakraborty RN, Langade D, More S, Revandkar V, Birla A. Efficacy of Cilnidipine (L\/N-type Calcium Channel Blocker) in treatment of hypertension: a meta-analysis of randomized and non-randomized controlled trials. Cureus. 2021;13:e19822.","journal-title":"Cureus"},{"key":"1150_CR105","volume":"14","author":"M Srivathsan","year":"2022","unstructured":"Srivathsan M, Vardhan V, Naseem A, Patil S, Rai V, Langade DG. Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers: A Meta-Analysis of Randomized Controlled and Retrospective Studies. Cureus. 2022;14:e27847.","journal-title":"Cureus"},{"key":"1150_CR106","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","volume":"37","author":"M Burnier","year":"2019","unstructured":"Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37:1574.","journal-title":"J Hypertens"},{"key":"1150_CR107","first-page":"2926","volume":"20","author":"JJ Lin","year":"2016","unstructured":"Lin JJ, Chang HC, Ku CT, Chen HY. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci. 2016;20:2926\u201334.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1150_CR108","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11892-018-0976-6","volume":"18","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. Type 2 Diabetes and Thiazide Diuretics. Curr Diab Rep. 2018;18:6.","journal-title":"Curr Diab Rep"},{"key":"1150_CR109","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.amjmed.2016.08.032","volume":"129","author":"C Bavishi","year":"2016","unstructured":"Bavishi C, Goel S, Messerli FH. Isolated systolic hypertension: an update after SPRINT. Am J Med. 2016;129:1251\u20138.","journal-title":"Am J Med"},{"key":"1150_CR110","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","volume":"65","author":"RHG Olde Engberink","year":"2015","unstructured":"Olde Engberink RHG, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJH. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015 May;65:1033\u201340.","journal-title":"Hypertension"},{"key":"1150_CR111","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385:2507\u201319.","journal-title":"N Engl J Med"},{"key":"1150_CR112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ahj.2022.07.006","volume":"254","author":"SY Wang","year":"2022","unstructured":"Wang SY, Hanna JM, Gongal P, Onuma OK, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. Am Heart J. 2022;254:30\u20134.","journal-title":"Am Heart J"},{"key":"1150_CR113","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","volume":"398","author":"M Nazarzadeh","year":"2021","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. The Lancet. 2021;398:1803\u201310.","journal-title":"The Lancet"},{"key":"1150_CR114","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/jch.12679","volume":"18","author":"X Zhang","year":"2016","unstructured":"Zhang X, Zhao Q. Association of Thiazide-Type diuretics with glycemic changes in hypertensive patients: a systematic review and meta-analysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich). 2016;18:342\u201351.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1150_CR115","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jacc.2015.10.083","volume":"67","author":"AK Pareek","year":"2016","unstructured":"Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, et al. Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. JACC. 2016;67:379\u201389.","journal-title":"JACC"},{"key":"1150_CR116","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/biomedicines13010053","volume":"13","author":"K Miyasako","year":"2025","unstructured":"Miyasako K, Maeoka Y, Masaki T. Recent advances and perspectives on the use of mineralocorticoid receptor antagonists for the treatment of hypertension and chronic kidney disease: a review. Biomedicines. 2025;13:53.","journal-title":"Biomedicines"},{"key":"1150_CR117","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41371-023-00891-1","volume":"38","author":"SS Shah","year":"2024","unstructured":"Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J. Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. J Hum Hypertens. 2024;38:383\u201392.","journal-title":"J Hum Hypertens"},{"key":"1150_CR118","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","volume":"80","author":"M Epstein","year":"2022","unstructured":"Epstein M, Kovesdy CP, Clase CM, Sood MM, Pecoits-Filho R. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am J Kidney Dis. 2022;80:658\u201366.","journal-title":"Am J Kidney Dis"},{"key":"1150_CR119","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2020","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2020;42:152\u201361.","journal-title":"Eur Heart J"},{"key":"1150_CR120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MNH.0000000000000557","volume":"29","author":"M Frimodt-M\u00f8ller","year":"2020","unstructured":"Frimodt-M\u00f8ller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2020;29:145.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1150_CR121","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70065","volume":"48","author":"M Ahmed","year":"2025","unstructured":"Ahmed M, Ahsan A, Shafiq A, Maniya MT, Jain H, Iqbal J, et al. Cardiovascular Efficacy and Safety of Finerenone: A Meta\u2010Analysis of Randomized Controlled Trials. Clin Cardiol. 2025;48:e70065.","journal-title":"Clin Cardiol"},{"key":"1150_CR122","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"1150_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100943","volume":"7","author":"P Amornritvanich","year":"2025","unstructured":"Amornritvanich P, Anothaisintawee T, Attia J, McKay GJ, Thakkinstian A. Efficacy of mineralocorticoid receptor antagonists on kidney and cardiovascular outcomes in patients with chronic kidney disease: an umbrella review. Kidney Med. 2025;7:100943.","journal-title":"Kidney Med"},{"key":"1150_CR124","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534\u201342.","journal-title":"J Hum Hypertens"},{"key":"1150_CR125","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejim.2023.04.021","volume":"113","author":"M Ahmed","year":"2023","unstructured":"Ahmed M, Nudy M, Bussa R, Filippone EJ, Foy AJ. A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension. Eur J Intern Med. 2023;113:83\u201390.","journal-title":"Eur J Intern Med"},{"key":"1150_CR126","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/08037051.2021.1880881","volume":"30","author":"M Lin","year":"2021","unstructured":"Lin M, Heizati M, Wang L, Nurula M, Yang Z, Wang Z, et al. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. Blood Press. 2021;30:145\u201353.","journal-title":"Blood Press"},{"key":"1150_CR127","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/dom.15518","volume":"26","author":"SR Bornstein","year":"2024","unstructured":"Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, et al. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial. Diabetes Obes Metab. 2024;26:2128\u201338.","journal-title":"Diabetes Obes Metab"},{"key":"1150_CR128","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","volume":"82","author":"L Marzano","year":"2025","unstructured":"Marzano L, Merlo M, Martinelli N, Pizzolo F, Friso S. Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review. Hypertension. 2025;82:e47\u201356.","journal-title":"Hypertension"},{"key":"1150_CR129","doi-asserted-by":"crossref","unstructured":"Lim H, Agustian H, Febriana V, Supit AI. Sacubitril\/valsartan role in patients with resistant hypertension: a systematic review. Hellenic Journal of Cardiology [Internet]. 2025. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1109966625000041 Jan 27 [cited 2025 May 30]; Available from:","DOI":"10.1016\/j.hjc.2025.01.004"},{"key":"1150_CR130","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10741-022-10273-3","volume":"28","author":"J Gao","year":"2023","unstructured":"Gao J, Zhao C, Zhang WZ, Liu S, Xin H, Lian ZX. Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2023;28:905\u201323.","journal-title":"Heart Fail Rev"},{"key":"1150_CR131","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/cells14090668","volume":"14","author":"A Cuttone","year":"2025","unstructured":"Cuttone A, Cannav\u00f2 V, Abdullah RMS, Fugazzotto P, Arena G, Brancati S, et al. Expanding the use of SGLT2 inhibitors in T2D patients across clinical settings. Cells. 2025;14:668.","journal-title":"Cells"},{"key":"1150_CR132","first-page":"100335","volume":"35","author":"I Hasan","year":"2024","unstructured":"Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS. SGLT2 inhibitors: Beyond glycemic control. J Clin Transl Endocrinol. 2024;35:100335.","journal-title":"J Clin Transl Endocrinol"},{"key":"1150_CR133","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40885-024-00279-4","volume":"30","author":"HY Lee","year":"2024","unstructured":"Lee HY, Ko SH, Park S, Kim K, Kim SY, Cho IJ, et al. The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension. Clin Hypertens. 2024;30:24.","journal-title":"Clin Hypertens"},{"key":"1150_CR134","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/ckj\/sfac069","volume":"15","author":"A Granata","year":"2022","unstructured":"Granata A, Maccarrone R, Anzaldi M, Leonardi G, Pesce F, Amico F, et al. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clin Kidney J. 2022;15:1657\u201365.","journal-title":"Clin Kidney J"},{"key":"1150_CR135","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, D\u00fcngen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42:3741\u201352.","journal-title":"Eur Heart J"},{"key":"1150_CR136","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5:333\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1150_CR137","doi-asserted-by":"publisher","first-page":"e1247","DOI":"10.52225\/narra.v4i3.1247","volume":"4","author":"RN Ramadhan","year":"2024","unstructured":"Ramadhan RN, Rampengan DD, Puling IM, Willyanto SE, Tjandra KC, Thaha M, et al. Efficacy of angiotensin receptor neprilysin inhibitor in hypertension management: A systematic review and meta-analysis of clinical trials. Narra J. 2024;4:e1247.","journal-title":"Narra J"},{"key":"1150_CR138","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/rcm.rcm_33_22","volume":"12","author":"TW Kao","year":"2023","unstructured":"Kao TW, Lee YC. Dose-dependent reduction of blood pressure by angiotensin receptor-neprilysin inhibitor: a network meta-analysis. Res Cardiovasc Med. 2023;12:19.","journal-title":"Res Cardiovasc Med"},{"key":"1150_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112219","volume":"224","author":"AY Su","year":"2025","unstructured":"Su AY, Csere MM, Shan R, Pasupuleti V, Valenzuela GV, Hernandez AV. Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2025;224:112219.","journal-title":"Diabetes Res Clin Pract"},{"key":"1150_CR140","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr. 2023;15:118.","journal-title":"Diabetol Metab Syndr"},{"key":"1150_CR141","volume":"16","author":"C Sreenivasan","year":"2024","unstructured":"Sreenivasan C, Parikh A, Francis AJ, Kanthajan T, Pandey M, AlQassab O, et al. Evaluating cardiovascular benefits of Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes mellitus: a systematic review. Cureus. 2024;16:e66697.","journal-title":"Cureus"},{"key":"1150_CR142","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1150_CR143","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/HJH.0000000000003903","volume":"43","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Toh KZX, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials. J Hypertens. 2025;43:290\u2013300.","journal-title":"J Hypertens"},{"key":"1150_CR144","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s43094-020-00151-w","volume":"6","author":"A Sharma","year":"2020","unstructured":"Sharma A, Mittal S, Aggarwal R, Chauhan MK. Diabetes and cardiovascular disease: inter-relation of risk factors and treatment. Future J Pharm Sci. 2020;6:130.","journal-title":"Future J Pharm Sci"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01150-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01150-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01150-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:02:42Z","timestamp":1781042562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01150-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":144,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01150-9","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Raghunath Dantu is a full-time employee of MEDEVA. He had no involvement in the scientific development of the consensus, including statement formulation, evidence appraisal, data interpretation, or decision-making. His contribution was limited to technical editorial and language-editing support after the scientific content was finalized.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}